Skip to main content

Table 1 Hepatic and renal function in wild-type (WT) mice and vehicle-treated, sodium vanadate (SV)-treated, L-ascorbic acid (L-AA)-treated, and L-AA+SV-treated spinal muscular atrophy (SMA) mice

From: Sodium vanadate combined with l-ascorbic acid delays disease progression, enhances motor performance, and ameliorates muscle atrophy and weakness in mice with spinal muscular atrophy

Groups

GOT (U/I)

GPT (U/I)

BUN (mg/dl)

CRE (mg/dl)

Reference range

54 to 298

17 to 77

8 to 33

0.2 to 0.9

Postnatal day 30

    

WT

55.67 ± 10.20

35.67 ± 6.67

19.82 ± 0.56

< 0.20

SMA (vehicle)

93.69 ± 20.28

30.16 ± 2.64

22.22 ± 0.77

0.23 ± 0.02

SMA (L-AA)

129.62 ± 33.65

31.15 ± 2.14

23.98 ± 0.91

0.26 ± 0.02

SMA (L-AA+SV)

119.87 ± 28.25

31.27 ± 2.99

22.80 ± 1.01

0.21 ± 0.03

Postnatal day 90

    

WT

125.40 ± 30.09

57.60 ± 7.63

24.38 ± 2.65

< 0.20

SMA (vehicle)

107.05 ± 18.45

42.20 ± 4.19

22.27 ± 0.90

< 0.20

SMA (L-AA)

169.54 ± 19.09

37.69 ± 2.96

24.32 ± 0.65

< 0.20

SMA (L-AA+SV)

143.50 ± 20.66

39.62 ± 3.85

25.17 ± 1.30

< 0.20

  1. Results were determined in at least five mice in each group, and the mean ± SEM was calculated. BUN = blood urea nitrogen; CRE = creatinine; GOT = glutamate oxaloacetate transaminase; GPT = glutamate pyruvate transaminase.